XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 19182

Change

-187.00 (-0.97)%

Market Cap

USD 0.14B

Volume

724.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+4.00 (+2.20%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+26.15 (+3.08%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.21 (+1.19%)

USD 617.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.09 (+0.61%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+20.00 (+0.98%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

-1.05 (-1.69%)

USD 266.08B
0QZO:LSE 0QZO

+1.70 (+1.53%)

USD 258.54B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.58% 82% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.58% 81% B- 75% C
Trailing 12 Months  
Capital Gain 6.39% 47% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.39% 46% F 54% F
Trailing 5 Years  
Capital Gain 64.71% 83% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.71% 81% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 8.42% 66% D+ 69% C-
Dividend Return 8.42% 66% D+ 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.66% 80% B- 89% A-
Risk Adjusted Return 126.32% 100% F 100% F
Market Capitalization 0.14B 51% F 44% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike